In Re Immune Response Securities Litigation

Good Law

375 F. Supp. 2d 983·2005 WL 1579484·2005 U.S. Dist. LEXIS 12602

United States District Court, Southern District of CaliforniaJune 7, 200501CV1237JWMCCalifornia20,676 words

Opinion

Jones, J.

ORDER: (1) DENYING DEFENDANTS’ MOTIONS TO DISMISS THE COMPLAINT; AND (2) DENYING DEFENDANTS’ REQUESTS FOR JUDICIAL NOTICE

This is a class action on behalf of all persons (“Plaintiffs”) who bought shares of Immune Response Corporation (“IRC”) between May 17, 1999 and July 6, 2001 (the “Class Period”). (Comply 1.) Plaintiffs allege IRC and its representatives made false and misleading statements about the efficacy of REMUNE — a drug IRC developed for the treatment of human immunodeficiency virus (“HIV”). Specifically, Plaintiffs allege securities fraud under the 1933 Securities Exchange Act §§ 11, 12(a)(2), and 15, as well as, Securities Exchange Commission (“SEC”) Rule 10b-5 and §§ 10(b), 20(a) of the 1934 Act. Defendants now move to dismiss under Fed.R.Civ.P. 12(b)(6) and 9(b). Plaintiffs oppose the Motions. For the reasons set forth below, Defendants’ Motions are DENIED.

Request for Judicial Notice

Defendants request incorporation by reference and judicial notice of various documents, some of which Plaintiffs oppose. As set forth below, the Court DENIES Defendants’ requests.

“As a general rule, a district court may not consider any material beyond the pleadings in ruling on a…

Sign in to read the full opinion

Create a free account to read the complete opinion text, citation history, and good-law status for this case.

Judges

Jones

Cites (91)

250 F.3d 668
968 F.2d 865
379 F.3d 672
360 F.3d 1090
146 F.3d 699
137 F.3d 616
283 F.3d 1079
164 F.3d 345
342 F.3d 903
762 F. Supp. 1359
221 F. Supp. 2d 1090
308 F. Supp. 2d 1168
250 F.3d 729
490 U.S. 319
640 F.2d 963
235 F.3d 845
308 F.3d 180
459 U.S. 519
380 F.3d 1226
320 F.3d 920
183 F.3d 970
223 F.3d 1020
284 F.3d 1027
103 F. Supp. 2d 425
927 F. Supp. 1297
425 U.S. 185
288 F.3d 385
298 F.3d 893
253 F.3d 423
327 F. Supp. 2d 1149
61 F. Supp. 2d 982
70 F.3d 1078
74 F.3d 955
988 F.2d 635
42 F.3d 1541
303 F. Supp. 2d 724
2 F. Supp. 2d 1345
184 F. Supp. 2d 980
95 F.3d 922
485 U.S. 224
102 F.3d 1478
216 F.3d 300
284 F.3d 72
49 F.3d 1363
252 F.3d 63
54 F.3d 1424
339 F.3d 933
125 S. Ct. 1627
940 F. Supp. 1101
175 F.3d 699
89 F.3d 1399
310 F. Supp. 2d 1106
154 F.3d 1191
55 F.3d 1402
336 F.3d 495
122 F.3d 363
320 F. Supp. 2d 646
999 F. Supp. 1342
26 F. Supp. 2d 910
272 F. Supp. 2d 928
78 F. Supp. 2d 976
1 F. Supp. 2d 1096
40 F. Supp. 2d 1160
970 F. Supp. 746
228 F.3d 1057
144 F.3d 1302
818 F.2d 1433
178 F. Supp. 2d 1077
353 F.3d 1125
144 F. Supp. 2d 848
501 U.S. 1083
35 F.3d 1407
82 F.3d 877
183 F. Supp. 2d 860
7 F.3d 357
977 F. Supp. 1031
477 U.S. 242
309 F.3d 1123
459 U.S. 375
103 F. Supp. 2d 193
130 F.3d 309
513 U.S. 561
604 F. Supp. 150
266 F. Supp. 2d 1150
903 F. Supp. 1361
599 F. Supp. 447
914 F.2d 1564
118 S. Ct. 2196
521 U.S. 642
268 U.S. 85
163 F. Supp. 2d 1079